ChromaDex Corporation (NASDAQ: CDXC) stock fell -7.41% on Friday to $1.75 against a previous-day closing price of $1.89. With 0.2 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.55 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.8700 whereas the lowest price it dropped to was $1.7500. The 52-week range on CDXC shows that it touched its highest point at $9.94 and its lowest point at $1.51 during that stretch. It currently has a 1-year price target of $7.56. Beta for the stock currently stands at 1.81.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CDXC was up-trending over the past week, with a rise of 3.55%, but this was down by -8.85% over a month. Three-month performance dropped to -11.62% while six-month performance fell -37.28%. The stock lost -81.62% in the past year, while it has lost -53.21% so far this year. A look at the trailing 12-month EPS for CDXC yields -0.40 with Next year EPS estimates of -0.17. For the next quarter, that number is -0.09. This implies an EPS growth rate of -23.80% for this year and 48.30% for next year.
Float and Shares Shorts:
At present, 68.31 million CDXC shares are outstanding with a float of 41.01 million shares on hand for trading. On Apr 28, 2022, short shares totaled 3.44 million, which was 5.03% higher than short shares on Mar 30, 2022. In addition to Mr. Frank Louis Jaksch Jr. as the firm’s Co-Founder & Exec. Chairman, Mr. Robert N. Fried serves as its CEO & Director.
Institutional Ownership:
Through their ownership of 33.42% of CDXC’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.01% of CDXC, in contrast to 31.33% held by mutual funds. Shares owned by individuals account for 21.72%. As the largest shareholder in CDXC with 4.90% of the stake, Yong Rong holds 3,346,153 shares worth 3,346,153. A second-largest stockholder of CDXC, BlackRock Fund Advisors, holds 2,920,929 shares, controlling over 4.27% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in CDXC, holding 2,689,208 shares or 3.94% stake. With a 1.96% stake in CDXC, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 1,336,529 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 1.09% of CDXC stock, is the second-largest Mutual Fund holder. It holds 742,094 shares valued at 1.24 million. Fidelity Small Cap Index Fund holds 0.55% of the stake in CDXC, owning 376,095 shares worth 0.63 million.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CDXC since 6 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With CDXC analysts setting a high price target of $11.00 and a low target of $5.75, the average target price over the next 12 months is $7.56. Based on these targets, CDXC could surge 528.57% to reach the target high and rise by 228.57% to reach the target low. Reaching the average price target will result in a growth of 332.0% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. CDXC will report FY 2022 earnings on 03/09/2023. Analysts have provided yearly estimates in a range of -$0.29 being high and -$0.38 being low. For CDXC, this leads to a yearly average estimate of -$0.33. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. ChromaDex Corporation surprised analysts by -$0.02 when it reported -$0.11 EPS against a consensus estimate of -$0.09. The surprise factor in the prior quarter was $0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.06 and the low estimate is -$0.10. The average estimate for the next quarter is thus -$0.08.
Summary of Insider Activity:
Insiders traded CDXC stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 1 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 25,000 while 0 shares were sold.
